These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 20462604)

  • 1. Role of COX-2 in tumorospheres derived from a breast cancer cell line.
    Singh B; Cook KR; Vincent L; Hall CS; Martin C; Lucci A
    J Surg Res; 2011 Jun; 168(1):e39-49. PubMed ID: 20462604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
    Singh B; Irving LR; Tai K; Lucci A
    J Surg Res; 2010 Oct; 163(2):235-43. PubMed ID: 20691996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
    Kalalinia F; Elahian F; Behravan J
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
    Wong TY; Li F; Lin SM; Chan FL; Chen S; Leung LK
    BMC Cancer; 2014 Jun; 14():426. PubMed ID: 24923427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
    Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
    Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
    Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
    Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
    Barnes NL; Warnberg F; Farnie G; White D; Jiang W; Anderson E; Bundred NJ
    Br J Cancer; 2007 Feb; 96(4):575-82. PubMed ID: 17285134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
    Dhawan D; Jeffreys AB; Zheng R; Stewart JC; Knapp DW
    Mol Cancer Ther; 2008 Apr; 7(4):897-904. PubMed ID: 18413803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells.
    Yang MY; Lee HT; Chen CM; Shen CC; Ma HI
    Int J Mol Sci; 2014 Jun; 15(6):11013-29. PubMed ID: 24945311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.
    Kundu N; Ma X; Kochel T; Goloubeva O; Staats P; Thompson K; Martin S; Reader J; Take Y; Collin P; Fulton A
    Breast Cancer Res Treat; 2014 Jan; 143(1):19-31. PubMed ID: 24281828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma.
    Zhou X; Zhou YP; Huang GR; Gong BL; Yang B; Zhang DX; Hu P; Xu SR
    Int J Gynecol Pathol; 2011 May; 30(3):262-70. PubMed ID: 21464727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    Hamy AS; Tury S; Wang X; Gao J; Pierga JY; Giacchetti S; Brain E; Pistilli B; Marty M; Espié M; Benchimol G; Laas E; Laé M; Asselain B; Aouchiche B; Edelman M; Reyal F
    J Clin Oncol; 2019 Mar; 37(8):624-635. PubMed ID: 30702971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.
    Bocca C; Bozzo F; Bassignana A; Miglietta A
    Mol Cell Biochem; 2011 Apr; 350(1-2):59-70. PubMed ID: 21140284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
    Xia W; Zhao T; Lv J; Xu S; Shi J; Wang S; Han X; Sun Y
    J Cell Biochem; 2009 Sep; 108(1):181-94. PubMed ID: 19562670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of tumorigenesis and oestrogen receptor-alpha expression by cell culture conditions in a stem cell-derived breast epithelial cell line.
    Wang KH; Kao AP; Chang CC; Lee JN; Chai CY; Hou MF; Liu CM; Tsai EM
    Biol Cell; 2010 Jan; 102(3):159-72. PubMed ID: 19895368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
    Chen C; Shen HL; Yang J; Chen QY; Xu WL
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):9-17. PubMed ID: 20229271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.
    Liu NB; Peng T; Pan C; Yao YY; Shen B; Leng J
    World J Gastroenterol; 2005 Oct; 11(40):6281-7. PubMed ID: 16419156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of COX-2 by RNAi modulates epithelial-mesenchymal transition in breast cancer cells partially dependent on the PGE2 cascade.
    Cao J; Yang X; Li WT; Zhao CL; Lv SJ
    Asian Pac J Cancer Prev; 2014; 15(22):9967-72. PubMed ID: 25520137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
    Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.